Objective: The aim of our study was to determine the relation of particular genetic variants in selected genes (GSTM1, GSTT1 null genotypes; rs1695 GSTP1; rs10735781 EVI5) to the risk of multiple sclerosis (MS) development and find out the possible association with disease disability progression rate.
INTRODUCTION
Multiple sclerosis (MS) is a progressive autoimmune disease of central nervous system characterized by neuroinflammation, demyelination and neurodegeneration. Factors triggering the disease onset and modulating variable disability progression rate in individual patients are still not fully elucidated. The MS symptoms are heterogenous and ambiguous, associated with the degree and localization of nerve tissue damage. Generally, there are distinguished several clinical MS forms, with the highest prevalence of relapsing-remitting form.
It is proposed that for the MS etiopathogenesis are responsible immune, environmental and genetic factors. Genetic factors associated with MS can be generally classified into HLA (human leukocyte antigen) genes and non-HLA genes [1] . Genetic predisposition to MS is represented mainly by a allele HLA-DRB1*1501, which is widely accepted as the most important susceptibility allele of MS [2, 3] . Gene products of non-HLA genes can contribute to the genetic risk of MS by modulation of different processes, including the regulation of T and B cells functions, cytokine signalization, oxidative stress, metabolism of vitamin D, iron metabolism, neuronal regeneration and many others [1] .
The aim of the present study was the analysis of selected non-HLA genetic variations in Slovak relapsing-remitting MS patients. Our choice included three antioxidant enzymes, known as glutathione-S-transferases (rs1695 GSTP1, null genotypes of GSTM1, GSTT1) and one candidate marker, single nucleotide polymorphism rs10735781 of EVI5 gene. EVI5 (ecotropic viral integration site 5) is a protein-coding gene, EVI5 protein is important for mitotic cytokinesis and cell signalization in immune pathways [4, 5] . All mentioned genetic changes have the potential association with disease onset or progression rate.
METHODS
Our study included 202 MS patients (age 39.86 ± 8.85) and 174 healthy control volunteers (age 34.94 ± 10.18). To evaluate the disease progression rate in patients, we used the widely accepted Multiple Sclerosis Severity Score (MSSS, range from 0.01 to 9.99) [6] that considers the neurological impairment of the functional systems (Expanded Disability Status Scale, EDSS) [7] together with disease duration. For the purposes of the association of these markers with the rate of disease disability progression, we stratified MS patients by MSSS score to three groups -slowly progressing MS (MSSS<3; n = 71), mid-rate progressing MS (MSSS 3-6; n = 98) and rapidly progressing MS (MSSS>6; n = 33). DNA from each patient was isolated from whole blood by commercial kit. Genotyping was performed by multiplex PCR reaction or PCR-RFLP method, with subsequent separation of amplified DNA fragments by gel electrophoresis. Primer sequences for multiplex PCR reaction: GSTM1 forward 5´-GAACTCCCTGAAAAGCTAAAGC-3´and reverse 5´-GTTGGGCTCAAATATACGGTGG-3´; GSTT1 forward 5´-TTCCTTACTGGTCCTCACATCTC-3´ and reverse 5´-TCACCGGATCAT GCCAGCA-3´; control fragment forward 5´-CAACTTCATCCACGTTCACC-3´ and reverse 5´-GAAGAGCCAAGGACAGGTAC-3´. rs1695 and rs10735781 were detected by PCR-RFLP method. Primer sequences for rs1695 GSTP1: forward 5´-GTAGTTTGCCCAAGGTCAAG-3á nd reverse 5´-AGCCACCTGAGGGGTAAG-3´, restriction cleavage was done by Alw26I enzyme. Primer sequences for rs10735781 EVI5: forward 5´-CCCCTCAGACTAACAGTGGA-3á nd reverse 5´-TTTGGTTTCTGTTGGTGTGG-3´, restriction cleavage was proceeded by AluI enzyme. Statistical analysis of the studied data was done using contingency tables with estimation of odds ratio and 95% confidence interval for the degree of association between two variabl es, p value was calculated by Fisher exact test and level of statistical significance was assumed as p≤0.05.
RESULTS
Our analysis of GSTM1 and GSTT1 null genotypes individually or in combination showed significant result in lower GSTT1 null genotype frequency in MS patients (13.9% vs. 22.4% in controls; OR 0.56; 95%CI 0.33 -0.95; p=0.04). Significant result was also detected in GSTM1, GSTT1 double null genotype (4% in MS patients vs. 11.5% in controls; OR 0.32; 95%CI 0.14 -0.74; p=0.006). Our results indicate that GSTT1 null genotype and double null genotype are protective in relation to multiple sclerosis. Focusing on various disease disability rate, GSTM1 null genotype is not predictive for any progression rate (p>0.05) and GSTT1 null genotype is predictive in association with middle progression rate (OR 0.48; 95% CI 0.24 -0.97; p=0.05), another results were not identified as significant (p>0.05). Frequency of GSTM1, GSTT1 double null genotype is significantly lower in subgroup of MS patients with slow progression rate (OR 0.22; 95%CI 0.05 -0.98; p=0.05) and middle (OR 0.33; 95%CI 0.11 -0.99; p=0.045). 
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DISCUSSION
The study of new MS genetic markers with possible diagnostic or prognostic importance, which may be helpful for early detection and monitoring of disease course or therapeutic responses, is still needed. Despite the huge research efforts, genetic basis of multiple sclerosis, which is considered to be the multifactorial disease, is still not clear, especially in cases of non-HLA candidate mutations or polymorphisms. Concerning to the Slovak MS patients, there are some results about non-HLA genetic changes. Allele C of rs6897932 in interleukin 7 receptor alpha chain (IL7Ra) gene was present in the higher frequency in MS patients (OR 1.31; 95 %CI 1.0 -1.72; p=0.047) and allele T is considered to be protective against MS development (OR 0.76; 95 %CI 0.58 -0.10; p=0.047). The genotype analysis showed that MS patients manifested a lower frequency of genotype CT when compared to controls or genotype TT and there was also been detected higher frequency of genotype CC. Authors found a significantly decreased risk of MS development in carriers of allele T with genotype CT (OR 0.87, 95 % CI 0.61 -1.23; p=0.05) or TT (OR 0.565; 95 % CI 0.28 -1.13; p=0.05). Moreover, minor allele T and genotype TT are protective against rapid disease disability progression in MS [8] . The findings about rs10735810 in vitamin D receptor gene in Slovak MS patients have shown the association of heterozygous FokI Ff genotype with increased risk of MS in women (OR 1.48; 95 % CI 1.01 -2.16; p=0.042). Despite it, there have not been found statistically significant differences in the proportions of FokI genotypes or allele frequencies between total MS patient and the control group. Authors also observed a trend of higher frequency of homozygotes FF in MS patients with rapid disease progression in comparison to the slow progressing MS patients (OR 1.93; 95 % CI 0.94 -3.94; p=0.071) [9] . The aim of our work was to analyse selected genetic changes (GSTM1, GSTT1 null genotypes; rs1695 GSTP1, rs10735781 EVI5) in a group of Slovak MS patients and to shed light on their potential importance for disease onset or disability rate. Certain genetic variations of glutathione-S-transferases with the negative influence on enzyme functions have been previously indicated as associated with multiple sclerosis, but their role in the etiopathogenesis of MS still remains controversial [10] [11] [12] . In group of 455 Serbian MS patients, GSTT1 null genotype and GSTM1, GSTT1 double null genotypes were observed in significantly higher frequency (p<0.0001 and p<0.05) when compared to 366 healthy people [12] . Another results from study of patients with North-European [11] or Greek origin [13] did not identify any relevant association of these changes with multiple sclerosis. Our results indicate the importance of GSTT1 null genotype (p=0.04) and double null genotype GSTM1, GSTT1 (p=0.006) for MS. Higher prevalence of null genotypes in control group suggests the protective role of these changes for MS onset and development, which is not in line with previously mentioned data [12] . We obtained significant result in GSTT1 null genotype and its association with mid-rate progression (p=0.05), also the frequency of GSTM1, GSTT1 double null genotype is significantly lower in subgroup of MS patients with progression rate defined as slow (p=0.05) and middle (p=0.045). GSTM1 null genotype did not show any significant association with disease onset or progression rate (p>0.05).
rs1695 of GSTP1 gene is a missense mutation with considerably negative impact on the enzyme activity and decreasing the catalytic functions. Research group [10] showed the significant association (p<0.05) of double recessive genotype (rs1695 and rs1800566 in NADPH quinine oxidoreductase 1) with the insufficient therapeutical response in group of 130 Greek MS patients. In group of North-European multiple sclerosis patients with disease duration more than 10 years has been observed significantly higher frequency of rs1695 dominant AA genotype and GSTM1 null genotype in combination (p=0.022) [11] . Another study focusing on rs1695 in Croatian MS patients did not prove any significant relation of this mutation with multiple sclerosis [14] . Based on our results, we did not suppose any significant association of recessive allele or genotype with MS development or disability progression in group of Slovakian patients (p>0.05).
According to ambiguity of available data [11, 13, 14] and highly polymorphous occurence of various changes in GST gene sequences in healthy population, which is accepted in general, we did not suggest direct association of these gene alterations with the MS onset or progression. Further research is needed for supporting these answers.
rs10735781 of EVI5 gene is the polymorphism indicated as predictive marker for multiple sclerosis. The association of risk genotype GG with European MS patients has been proved by association studies and meta-analyses [15] [16] [17] . Significant results are described in Dutch population (p=0.02) [16] and also by genome-wide association study of MS patients with English or American origin (p=0.000335) [15] . Similar results about the association of risk genotype GG with disease onset are showed in Americans with African origin (p=0.006) [17] . Results of our work are not in line with previously mentioned data. We did not find any significant association of risk allele G or genotype GG with disease onset or disability progression in Slovak MS patients (p>0.05).
In summary, we can conclude that particular non-HLA genetic variants can be important for evaluation of the risk of MS development and disability progression. Positive or negative prognostic genetic markers also improve the diagnostic and therapeutic procedure and can help to minimize neurological damage in predisposed individuals.
